RxDoctor Payments Data

Stacey Shoop

Medical · Santa Ana, CANPI 1104222124

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (41.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Angiodynamics, Inc. at 41.1% of the total. Reporting peaked in 2023 at $22,331 and has fallen 74.7% since, to $5,658 in 2025. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,815in general payments, 2019–2025

Across 775 payments — averaging $84.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$27K
  • Amgen$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Edwards Lifesciences$5K
  • Medtronic$3K
  • Novo Nordisk$3K
  • plus $9K from 34 others

What the payments were for

  • Consulting fees$5,7259%
  • Speaking & faculty fees$15,40023%
  • Travel & lodging$2190%
  • Food & beverage$17,11926%
  • Education$2970%
  • Other$27,05641%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,815 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin248$275,927
OzempicSemaglutide145$144,114
XareltoRivaroxaban128$122,138
EntrestoSacubitril/Valsartan80$90,548
FarxigaDapagliflozin Propanediol99$82,541
RybelsusSemaglutide21$51,368
KerendiaFinerenone29$34,948
EliquisApixaban38$33,772
MounjaroTirzepatide23$30,368
VascepaIcosapent Ethyl70$29,403
TrulicityDulaglutide27$25,714
Repatha SureclickEvolocumab43$24,793
Icosapent Ethyl89$19,789
VerquvoVericiguat11$19,084
Repatha SyringeEvolocumab13$7,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$931$275,927248 claims
Novo NordiskOzempic, Rybelsus$2,964$195,482166 claims
Johnson & JohnsonXarelto$1,088$122,138128 claims
NovartisEntresto$730$90,54880 claims
AstraZenecaFarxiga$654$82,54199 claims
Lilly USA, LLCMounjaro, Trulicity$668$56,08250 claims
BayerKerendia$366$34,94829 claims
PfizerEliquis$171$33,77238 claims
MerckVerquvo$482$19,08411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.

Other medical in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →